A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Cyclophosphamide (Primary) ; Pidilizumab (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2016 Status changed from recruiting to suspended.
- 13 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 15 Nov 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.